Supporting Start-ups in Drug Development

Early-stage start up biotechs are driving some of the most exciting innovation in therapeutics — but they also face unique barriers that slow progress, increase risk, and strain lean internal teams. Our start-up support model is built specifically to address these challenges, accelerate development, and help founders reach clinical and commercial milestones with confidence.

Schedule a Call
hVIVO_Regulatory_Consulting_Services

Supporting Start-ups in Drug Development

Early-stage start up biotechs are driving some of the most exciting innovation in therapeutics — but they also face unique barriers that slow progress, increase risk, and strain lean internal teams. Our start-up support model is built specifically to address these challenges, accelerate development, and help founders reach clinical and commercial milestones with confidence.

Challenges hVIVO can solve for Start-ups

Limited Internal Resources & Specialist Bandwidth

Senior scientific, clinical, and regulatory experts embedded as an extension of your team

 

- Access to translational, PK/PD, assay development, statistics, and regulatory specialists

- Practical support to maintain programme momentum

Uncertainty Around Strategy, Prioritisation & Pathway Design

Regulatory consulting 

- Drug Development Roadmaps

- Challenge of scientific assumptions

- Integrated scientific, clinical, regulatory decision-making

Funding Pressure & the Need for Compelling Data

Investor-aligned programme design

- High-quality laboratory and translational data

- Predictable timelines for fundraising cycles

Operational Complexity & GxP Execution Risk

An Early Phase ecosystem for clinical conduct 

 

- Operational ownership from design to delivery

- Integrated Phase I and challenge infrastructure

- GCP/GCLP processes and QA oversight

Regulatory Inexperience

Start-ups often lack regulatory specialists, leading to gaps discovered too late.


Access to senior regulatory strategists

- IND/CTA design and document preparation

- Early regulatory risk identification

Translational & Scientific Risk

Programmes can derail due to unvalidated MoA, unclear biomarkers, missing assays, or endpoints that don’t translate.

- Biomarker strategy, modelling, endpoint definition

- Assay development and validation

- Access to virology, immunology, respiratory experts

Fragmented Vendor Landscape

Start-ups often juggle separate providers across toxicology, labs, regulatory, and clinical needs.

 - Single integrated partner

- Cohesive communication and oversight


.

Compressed Timelines & Investor Expectations

Start-ups need rapid progress to maintain momentum.

- Fast start-up processes

- Predictable milestones

- Delivery aligned with fundraising timelines

Why Founders Choose hVIVO

  • Built for speed, agility, scientific rigor
  • Deep cross-functional expertise
  • Integrated ecosystem: laboratory, modelling, regulatory, and clinical
  • Proven delivery for early-stage start-ups and biotechs
contact-bg-image

Structured support for what's next | De-risk your next milestone

Investor Readiness

 Expert investor readiness consulting with strategic documents, due-diligence preparation, forecasting, and guidance for early biotech’s and start-ups.  

Translational Consulting Research

Translational consulting bridging R&D to GLP/GCP standards.

Laboratory Services Biomarker strategy, assay development, validation, and scientific/regulatory guidance. 

Speed-to-Clinic Accelerator

Our Speed‑to‑Clinic Accelerator provides an integrated, expert‑led pathway from early research to first‑in‑human trials.  

Due Diligence & Gap Analysis

Already have your strategy and documents in place? Get a focused, independent gap analysis (mock due diligence) — the same review real investors and pharma partners will run — to find and fix critical gaps before they do. 

FAQ

Still have questions?
Get in touch with us
We work with seed‑stage, Series A/B biotechs, academic spin-outs, platform technology developers, and early therapeutic companies who need scientific, regulatory, or operational support to progress toward IND/CTA and early‑phase clinical studies.
The ideal time is before major programme‑defining decisions — such as biomarker selection, assay development, IND‑enabling study design, or preparing investor milestones. Early engagement prevents rework and ensures strategic alignment.
Start-ups often run lean. Our integrated ecosystem gives founders immediate access to senior scientific, regulatory, and clinical specialists without needing to build in‑house capabilities, accelerating progress while reducing risk.
Yes — we provide continuous access to regulatory strategists, IND/CTA planning, document authoring, and scientific advice preparation, ensuring regulatory expectations are met early and consistently.
Yes. We support strategy, planning, lab work, modelling, and early clinical delivery under one group. This removes vendor fragmentation and keeps programmes moving efficiently from concept to clinic.
We design programmes aligned with value-inflection milestones and deliver GCP/GCLP‑compliant laboratory and clinical outputs trusted by investors, partners, and regulators. Our predictable timelines help companies plan fundraising rounds with confidence.

Investor Readiness is the full build — we help develop your Target Product Profile, Drug Development Plan, and Regulatory Roadmap, plus clinical development forecasting and scenario-based budgeting, so you have a complete, investor-grade strategic package before you start raising. Due Diligence & Gap Analysis is narrower and can stand alone: if your strategy and documents are already in place, we run the same cross-functional review a real investor or pharma partner would — scientific, CMC, non-clinical, clinical, and regulatory — scoped to a single discipline or the full assessment depending on what you need checked. We've completed 80+ due diligence projects (150+ including gap analysis) across small molecules, biologics, ADCs, ATMPs, and combination products, with full evaluations delivered in as little as two weeks. The two aren't mutually exclusive — you can use Investor Readiness to build the case, then come back for Due Diligence & Gap Analysis later to pressure-test it, or go straight for the gap analysis if your strategy's already solid. Explore Due Diligence & Gap Analysis Services →

Contact Us